Biocytogen

🧬 Empowering IBD Therapies: Biocytogen's Humanized Mice Targeting the TL1A Pathway🚀 TL1A therapies are making waves in the fight against inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis! Several TL1A inhibitors—including monoclonal and bispecific antibodies like duvakitug, tulisokibart, PF-07261271, and FG-M701—are under development to address unmet needs in IBD. TL1A plays a crucial role in immune regulation by activating pathways involved in cell proliferation, apoptosis, and cytokine production, offering promising therapeutic opportunities. At Biocytogen, we’re advancing IBD research with our humanized mouse models targeting TL1A signaling pathways and robust IBD models developed using diverse induction methods across genetic backgrounds. These models support preclinical research and efficacy evaluation, accelerating innovation in IBD therapies. Contact us to learn more about how our models can drive your research forward! 🌍✨ Read more about TL1A: https://lnkd.in/e-QYNRim #Biocytogen #TL1A #IBD #InflammatoryBowelDisease #IBDResearch #HumanizedMice #DrugDiscovery #InnovationInBiotech #AutoimmuneTherapies #CrohnsDisease #UlcerativeColitis

Innovating Monkeypox Virus Therapies with Antibodies from RenMab® Mice The global impact of the monkeypox virus (MPXV) continues to escalate, with over 100,000 reported cases. Despite the approval of two vaccines, a critical shortage persists, and no FDA-approved treatment is currently available. The development of new therapies is urgently needed. Biocytogen is tackling this challenge head-on with its RenMab® mice. Using rapid screening with Beacon® technology, we’ve developed over 100 candidate antibody sequences targeting critical proteins of the monkeypox virus, such as B6 and A35. These antibodies demonstrate effective neutralization of MPXV in vitro, offering hope for novel treatments. 🌟 Contact us today to learn more about our MPXV antibodies, explore licensing or co-development opportunities, and access the latest validation data! #Monkeypox #BiotechInnovation #AntibodyTherapy #RenMab #InfectiousDiseases #ViralTherapeutics #Biocytogen #CoDevelopment #PublicHealth 🌍💉

#BehindTheScene🚴♂️ Meet Nishit: Foodie, Biker, and Innovator at Biocytogen! 🍕🔬 Nishit Singh’s journey is as vibrant as his love for food and biking! Whether savoring Boston’s culinary delights, indulging in his favorite Indian dishes, or cruising along the scenic Charles River, Nishit brings an infectious energy to every aspect of his life. His passion for exploration fuels both his personal adventures and his professional drive at Biocytogen. From tackling complex experiments to collaborating with senior scientists, Nishit’s dedication and zest for life shine through in everything he does. At Biocytogen, Nishit thrives by combining curiosity, creativity, and hard-earned skills. From mastering advanced techniques like flow cytometry and ELISA to balancing multiple projects with precision, his career is built on a solid foundation of time management and collaboration. Nishit’s advice? Stay curious. Whether you’re analyzing unexpected data or diving into the latest research, a curious mindset can transform challenges into opportunities and keep the magic of discovery alive. Read more: https://lnkd.in/eTBSQRqf #Biocytogen #BiotechInnovators #FoodieScientist #CareerJourney #ScientificDiscovery #InnovationInBiotech #StayCurious

2024 Biopharma M&A Trends: Deals and Big Moves 🚀💊 In 2024, the biopharma M&A landscape remained active, with a strong emphasis on immunology and oncology. Here are the key highlights from the top 10 deals: - Novo Holdings made a bold $16.5B move to acquire Catalent, marking the year’s biggest deal by value. - Sanofi streamlined its focus by selling a 50% stake in Opella for €8B to CD&R. - Vertex added Alpine Immune Sciences for $4.9B, expanding its autoimmune pipeline. - Gilead Sciences acquired CymaBay Therapeutics for $4.3B, leveraging its liver disease expertise to launch Livdelzi, a promising treatment for primary biliary cholangitis. - Eli Lilly secured Morphic Therapeutics for $3.2B, pushing its IBD treatments forward. - Merck acquired EyeBio for $3B, diversifying into eye diseases with promising candidates. - Roquette acquired International Flavors & Fragrances' Pharma Solutions for $2.85B, boosting its pharma excipients portfolio and health and nutrition presence. - Novartis and MorphoSys sealed a €2.7B deal to advance oncology therapies. - Lundbeck acquired Longboard Pharmaceuticals for $2.5B, targeting epilepsy with promising treatments. - Ono Pharmaceutical bought Deciphera Pharmaceuticals for $2.4B to boost its oncology portfolio. The trend of 2024 Biopharma M&A focused on innovative treatments and strategic growth. Stay tuned for more impactful M&A as we head into 2025! 🔬 #Biopharma #MergersAndAcquisitions #Oncology #Immunology #DrugDevelopment #InnovativeTreatments #Biotech #PharmaDeals #2024M&A

🧧 Happy Chinese New Year from Biocytogen! 🎆🐍 As we celebrate the Year of the Snake, we want to take this opportunity to thank our incredible partners, collaborators, and the biotech community. Your trust, support, and dedication have been the driving force behind the breakthroughs we’ve achieved together—making a meaningful impact on lives worldwide. Looking ahead, we’re excited for the opportunities and innovations the new year will bring! At Biocytogen, collaboration and shared purpose are at the heart of everything we do. From advancing research to creating innovative therapies, every success we’ve reached has been made possible by the unwavering efforts of our team and partners. We wish you and your families joy, success, and prosperity in the year to come. Thank you for being an essential part of our journey. Let’s make this Year of the Snake one to remember—Happy Chinese New Year! 🐍🧨✨ #HappyChineseNewYear #YearOfTheSnake #Biocytogen #BiotechCommunity #Innovation #Collaboration #Gratitude

🌟 Mark Your Calendar! Webinar on Expanding Tumor Antigen Targeting with TCR-Mimic Antibodies 🌟 How can we break the limitations of traditional antibody therapies to target intracellular tumor antigens? Discover the transformative potential of Biocytogen’s fully human RenMice platform in advancing TCR-mimic antibody discovery! 📅 Date & Time: Wed, Feb 12, 11:00 AM EST 🎙️ Speaker: Dr. Wanbo Tang 👉 Register now: https://lnkd.in/e9nXTUPV 🎯 What You’ll Learn: - Limitations of traditional antibody therapies. - Biocytogen’s TCR-mimic platform for generating fully human TCRm antibodies. - How TCRm antibodies expand targetable antigens in cancer immunotherapy. - Case studies showcasing the applications of TCRm antibodies. #Webinar #TCRmAntibodies #RenMice #CancerImmunotherapy #Biocytogen #PharmaceuticalResearch #AntibodyDiscovery #TumorImmunotherapy #DrugDevelopment 

🎉 Kicking Off the New Year with Gene-ius Break Watertown! 🎊 A heartfelt thank you to everyone who joined us at Biocytogen’s first 2025 Gene-ius Break Dinner Party in Boston! We were thrilled to welcome around 200 clients, partners, and prospects to celebrate the start of the year on an inspiring and collaborative note. Your energy and enthusiasm made the evening a true success, filled with engaging conversations and shared excitement about the latest advancements in biotech. We’ve received incredible feedback from our attendees, highlighting the event’s value and the meaningful connections it fostered. A huge shoutout to our amazing team for their incredible efforts in organizing the event and ensuring everything ran seamlessly. This was truly a team effort, and your hard work didn’t go unnoticed! Here’s to more opportunities for collaboration and groundbreaking achievements as we dive into 2025. Stay tuned for future events—we can’t wait to see you again. Cheers to a year filled with innovation and success! 🥂 #GeneiusBreak #Biocytogen #BiotechNetworking #NewYearNewGoals #Innovation #DrugDiscovery #Collaboration

🌍 Advancing Psoriasis Treatment with Fully Human Antibodies by Biocytogen 🧬 Psoriasis is a chronic skin condition affecting 2–3% of the global population, characterized by erythema, silvery-white scales, and itching. Its pathogenesis involves abnormal immune activation, where impaired skin barrier function activates pDCs and mDCs, stimulating Th1 and Th17 cells and driving cytokine-driven inflammation. This further activates keratinocytes to produce antimicrobial peptides, cytokines, and chemokines, amplifying the inflammatory response. As understanding deepens, new therapeutic targets and treatments are emerging. Biocytogen’s RenBiologics™ platform is at the forefront of psoriasis treatment innovation, developing fully human antibodies targeting psoriasis-related pathways, such as IL36R, IL25, and CD6. Let’s collaborate to accelerate breakthroughs—explore licensing, evaluation, or co-development opportunities with Biocytogen today! #PsoriasisTreatment #FullyHumanAntibodies #Biocytogen #Innovation #Immunotherapy #RenMice #Inflammation

At SOTIO, we’re dedicated to transforming cancer care through our pioneering antibody-drug conjugate (#ADC) therapies. ADCs combine the precision of targeted antibodies with the power of cytotoxic payloads to selectively destroy cancer cells, saving healthy tissues and improving patient outcomes. SOTIO’s in-house protein engineering capabilities and our recent collaboration with Biocytogen allows us to integrate bispecific antibodies into ADCs and fine-tune the targeting of two different cancer antigens at the same time. The evolution of our ADC platform demonstrates our ongoing dedication to tackling the most challenging forms of #cancer. Stay tuned as we continue progressing our portfolio of ADCs: https://lnkd.in/d-UPGwb #CancerResearch #Biotechnology #jsmePPF